

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

UROGEN PHARMA LTD., and UROGEN
PHARMA, INC.,

Plaintiffs,

v.

TEVA PHARMACEUTICALS, INC.,
TEVA PHARMACEUTICALS USA, INC.,
and TEVA PHARMACEUTICAL
INDUSTRIES LTD.

Defendants.

Civil Action No. _____

**SUPPLEMENTAL INFORMATION FOR PATENT CASES
INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiffs hereby provide the information below with respect to the deadlines set forth
in 21 U.S.C. 355(j):

Date Patentee(s) Received Notice: February 25, 2024

Date of Expiration of Patents: January 20, 2031

Stay Deadline: No earlier than April 15, 2027¹

¹ Current expiration of Orphan Drug Exclusivity.

Dated: April 2, 2024

MCCARTER & ENGLISH, LLP

OF COUNSEL:

/s/ Daniel M. Silver

William E. Solander
Daniel J. Minion
Katherine E. Adams
Justin M. Dersh
Philip J. Dutko
VENABLE LLP
151 West 42nd Street, 49th Floor
New York, NY 10036
(212) 307-5500

Daniel M. Silver (#4758)
Alexandra M. Joyce (#6423)
Renaissance Centre
405 N. King St., 8th Floor
Wilmington, DE 19801
(302) 984-6300
dsilver@mccarter.com
ajoyce@mccarter.com

Attorneys for Plaintiffs

Evan S. Krygowski
VENABLE LLP
600 Massachusetts Ave., NW
Washington, DC 20001
(202) 344-4000